van der Kuip H - Search Results

1

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.

Fritz P, Cabrera CM, Dippon J, Gerteis A, Simon W, Aulitzky WE, van der Kuip H. Fritz P, et al. Among authors: van der kuip h. Breast Cancer Res. 2005;7(3):R374-84. doi: 10.1186/bcr1012. Epub 2005 Mar 21. Breast Cancer Res. 2005. PMID: 15987433 Free PMC article.

2

Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.

van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE. van der Kuip H, et al. BMC Cancer. 2006 Apr 7;6:86. doi: 10.1186/1471-2407-6-86. BMC Cancer. 2006. PMID: 16603054 Free PMC article.

3

Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE. Sonnenberg M, et al. Among authors: van der kuip h. BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364. BMC Cancer. 2008. PMID: 19077243 Free PMC article.

4

Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin.

Schmid JO, Dong M, Haubeiss S, Friedel G, Bode S, Grabner A, Ott G, Mürdter TE, Oren M, Aulitzky WE, van der Kuip H. Schmid JO, et al. Among authors: van der kuip h. Cancer Res. 2012 Nov 15;72(22):5824-32. doi: 10.1158/0008-5472.CAN-12-1201. Epub 2012 Sep 7. Cancer Res. 2012. PMID: 22962266

5

Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.

Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE. Goetz AW, et al. Among authors: van der kuip h. Cancer Res. 2001 Oct 15;61(20):7635-41. Cancer Res. 2001. PMID: 11606405

6

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE. Wohlbold L, et al. Among authors: van der kuip h. Blood. 2003 Sep 15;102(6):2236-9. doi: 10.1182/blood-2002-12-3899. Epub 2003 May 15. Blood. 2003. PMID: 12750174 Free article.

7

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.

van der Kuip H, Wohlbold L, Oetzel C, Schwab M, Aulitzky WE. van der Kuip H, et al. Am J Pharmacogenomics. 2005;5(2):101-12. doi: 10.2165/00129785-200505020-00003. Am J Pharmacogenomics. 2005. PMID: 15813673 Review.

8

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Henkes M, van der Kuip H, Aulitzky WE. Henkes M, et al. Among authors: van der kuip h. Ther Clin Risk Manag. 2008 Feb;4(1):163-87. Ther Clin Risk Manag. 2008. PMID: 18728706 Free PMC article.

9

Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.

Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H. Skorta I, et al. Among authors: van der kuip h. Cancer Res. 2009 Dec 15;69(24):9337-45. doi: 10.1158/0008-5472.CAN-09-0548. Cancer Res. 2009. PMID: 19934315

10

Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4.

Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE, van der Kuip H. Gutekunst M, et al. Among authors: van der kuip h. Cancer Res. 2013 Mar 1;73(5):1460-9. doi: 10.1158/0008-5472.CAN-12-2876. Epub 2013 Jan 9. Cancer Res. 2013. PMID: 23302226 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters